COVID-19

Pfizer-BioNTech to seek approval of the first Covid vaccine for young children “in the coming weeks” – Forbes France

vaccine |
Source: Getty Images

The companies behind the Pfizer vaccine are almost ready to apply for permission to use the vaccine in children as young as five years old and are expected to apply in the coming weeks, the founders of vaccine maker BioNTech said in an interview published Friday.

Main aspects

  • The founders of BioNTech, who worked with Pfizer to develop the vaccine, told the German weekly Der Spiegel that the company would present the results of its trial of the vaccine in children ages five to eleven and seek worldwide approval of the vaccine. “In the next weeks”. .
  • “Things are looking good, everything is going according to plan,” BioNTech managing director Ugur Sahin said, adding that the raw data is currently being prepared for regulatory filing.
  • Özlem Tureci, BioNTech’s chief medical officer, said the companies are working to produce smaller doses of the vaccine for approval by authorities.
  • The company also plans to apply for approval of the vaccine for children ages six months to two years later this year.

The context

The increase in coronavirus cases and hospitalizations in children has made it more urgent to approve the vaccine in younger people. Although serious illnesses and deaths from the virus remain extremely rare, the number of children hospitalized with Covid-19 is higher than at any other time in the pandemic. Data from the Department of Health and Human Services shows that more than 2,500 children are currently admitted to the hospital with suspected or confirmed Covid-19. This situation, associated with a resurgence of the respiratory syncytial virus (RSV), has overwhelmed pediatric facilities.

Important figure

251 781. This is the number of children who tested positive for Covid-19 last week. Children represent a growing proportion (about 27%) of all new cases in the United States.

What to watch out for

Moderna is also looking to make its vaccine available to children under 12 years of age. The company announced Thursday that it has already recruited all participants in a trial testing its vaccine for children ages 6 to 11.

Forbes US Translated Article – Author: Jemima McEvoy

<< Lea también: Covid-19: África recibirá un 25% menos de dosis de vacuna de lo esperado, según la OMS >>>

Back to top button